Document Detail


Add-on-therapy with bevacizumab in children and adolescents with poor prognosis non-CNS solid tumors.
MedLine Citation:
PMID:  23154263     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Bevacizumab is increasingly being used in adult patients with cancer and children with central nervous system (CNS) tumors. Little, however, is known about the efficacy, risks, and benefits of bevacizumab administration in non-CNS tumors of childhood. The aim of the present study was to report on bevacizumab administered as add-on-therapy for poor prognosis non-CNS solid tumors of childhood and adolescence, including a prospective evaluation of side effects of bevacizumab. Seven patients (female: n = 5; median age, 14.5 years) with relapsed (n = 4) or primary metastatic (n = 3) solid non-CNS tumors received bevacizumab at 5-10 mg/kg body weight intravenously every 2-3 weeks. Assessment of cardiac function, thyroid hormone levels, urine analysis, and radiographic responses were carried out every 3 months. The median time of bevacizumab treatment was 10 (range, 5-17) months. Patients received a median of 16 (range, 10-38) bevacizumab infusions. With a median follow-up of 25 (range, 13-38) months, five patients relapsed after 7-25 months and three of them died. Two patients are still in complete remission for 31 and 32 months, respectively. Fraction shortening decreased in two patients. Bevacizumab was associated with new-onset increase in basal thyroid-stimulating hormone (n = 3), mild proteinuria/hematuria (n = 5), intermittent hypertension (n = 2), hypertension requiring antihypertensive medication (n = 3), and epistaxis (n = 2). In two patients, therapy with bevacizumab was terminated because of side effects. Selected patients with relapsed or primary metastatic solid non-CNS tumors of childhood and adolescence might benefit from add-on-therapy with bevacizumab. Although the side effects were usually mild, cardiac monitoring seems to be essential during and after the administration of bevacizumab.
Authors:
Jasmin Pansy; Peter Fritsch; Petra Sovinz; Herwig Lackner; Wolfgang Schwinger; Christian Urban; Martin Benesch
Related Documents :
8262833 - Outcome and prognostic factors in soft tissue sarcoma in the adult.
25087673 - Commentary on "intermittent versus continuous androgen deprivation in prostate cancer."...
18303733 - A case of renal melanoma metastasis: description of clinico-pathological features.
Publication Detail:
Type:  Clinical Trial; Journal Article    
Journal Detail:
Title:  Anti-cancer drugs     Volume:  24     ISSN:  1473-5741     ISO Abbreviation:  Anticancer Drugs     Publication Date:  2013 Feb 
Date Detail:
Created Date:  2012-12-14     Completed Date:  2013-05-23     Revised Date:  2013-05-27    
Medline Journal Info:
Nlm Unique ID:  9100823     Medline TA:  Anticancer Drugs     Country:  England    
Other Details:
Languages:  eng     Pagination:  198-203     Citation Subset:  IM    
Affiliation:
Department of Pediatrics and Adolescent Medicine, Division of Pediatric Hematology and Oncology, Medical University of Graz, Graz, Austria. jasmin.pansy@medunigraz.at
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adolescent
Angiogenesis Inhibitors / adverse effects*,  therapeutic use*
Antibodies, Monoclonal, Humanized / adverse effects*,  therapeutic use*
Central Nervous System Neoplasms / drug therapy*,  metabolism,  radiotherapy,  surgery
Child
Combined Modality Therapy
Female
Follow-Up Studies
Humans
Male
Prognosis
Prospective Studies
Thyrotropin / metabolism
Young Adult
Chemical
Reg. No./Substance:
0/Angiogenesis Inhibitors; 0/Antibodies, Monoclonal, Humanized; 2S9ZZM9Q9V/bevacizumab; 9002-71-5/Thyrotropin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Animal models for HIV/AIDS research.
Next Document:  Impact of 3D Conformal Radiotherapy on Lung Function of Patients with Lung Cancer: A Prospective Stu...